Female Urology, Urodynamics, Incontinence, and Pelvic Floor Reconstructive SurgeryThree-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation
Section snippets
Methods
Enrollment criteria and design were published previously.2, 3 Subjects had a primary diagnosis of OAB as demonstrated on a 3-day voiding diary demonstrating ≥ 8 voids per day (urgency frequency, UF) and/or ≥ 2 involuntary leaking episodes in 72 hours (urinary incontinence, UI).
Institutional Review Boards approved the protocol and informed consent forms were signed prior to participation in study activities. All subjects underwent a staged implant procedure with the InterStim System
Results
Overall, 340 subjects received test stimulation and 272 subjects were implanted with the InterStim System. Baseline demographics are listed in Supplementary Table S1. Subjects had tried a median of 2 OAB medications prior to full system implant. On average, UI subjects had 3.1 ± 2.7 leaks/day; UF subjects had 12.6 ± 4.5 voids/day at baseline. There were 217 subjects followed up until 36 months, with 193 subjects with a voiding diary at baseline and at 36 months. Seventeen subjects who
Discussion
OAB is a chronic condition that must be managed successfully over time to provide meaningful benefit. This prospective study demonstrates sustained safety and efficacy of SNM in OAB subjects after 36 months of treatment and will continue to follow study subjects up to 60 months. There is minimal drop-off in therapeutic success when compared to results at 1 year.3 Improvements in QOL, sexual function in female subjects, and pelvic pain measures were sustained. The rate of device-related AE (47%)
Conclusion
The InSite trial is an ongoing, large, prospective multicenter study designed to evaluate the long-term safety and efficacy of SNM for subjects with refractory symptoms of OAB. This paper reports the results after 3 years of therapy, demonstrating that implanted subjects maintained improvements in OAB symptoms and QOL. Whereas the rate of AEs and the need for reoperation are acknowledged concerns related to this therapy, they are reduced compared to prior studies.
References (14)
- et al.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment
J Urol
(2015) - et al.
Sexual dysfunction in men with lower urinary tract symptoms
J Clin Epidemiol
(1998) - et al.
Measurement of health status. Ascertaining the minimal clinically important difference
Control Clin Trials
(1989) - et al.
Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study
J Urol
(2007) - et al.
Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study
J Urol
(2013) - et al.
Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder
Neurourol Urodyn
(2015) - et al.
Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder
Neurourol Urodyn
(2016)
Cited by (0)
Financial Disclosure: Steven Siegel is a patent holder at MDT, BSI, and QIG; and has received consulting fees from MDT, Allergan, and NuVectra, and speaking fee/proctor from MDT and QIG. He has also contracted research for MDT and IPSEN. Karen Noblett received consulting fees from MDT, Axonics, and speaking fee/proctor from MDT and BSI. She also contracted research for MDT. Suzette E. Sutherland is a study investigator for Medtronic and Allergan, and a paid consultant for Medtronic, Allergan, and Axonics. Jason Bennett is a study investigator and consultant for Medtronic, and a consultant for Intuitive. Fangyu Kan and Elizabeth Thiery are employees of Medtronic. The remaining authors declare that they have no relevant financial interests.
Funding Support: Medtronic, Inc., sponsored this study in full.
ClinicalTrials.gov identifier: InSite for Overactive Bladder, NCT00547378.